Summary:
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of LY3972406 in Adults with Moderate-to-Severe Plaque Psoriasis
Criteria:- 18-75 years of age
- Moderate-to-severe chronic plaque psoriasis for at least 6 months
- BMI within the range of 18 to 40 kg/m²
Qualified Participants May Receive:
- Compensation for time and travel
- Study-related care at no cost